PrimeVax is a clinical stage biotechnology company with our first indication for PD-1 failed melanoma. We opened our first IND with the FDA and are currently mobilizing our clinical trial sites. A non-confidential slide deck may be provided for potential partnership contacts.
For business development inquiries, please email:
investorrelations@primevax.com